By promoting insulin release and inhibiting glucagon secretion, GLP-1 agonists effectively lower blood sugar levels, providing a valuable therapeutic option for individuals with type 2 diabetes
Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders
PubMed Central, Heo, Chan Uk, and Chang-Ik Choi
The hypothesis regarding the impact of GLP-1 RAs on depression suggests a complex interaction within the dopaminergic system
Microdosing drastically reduces these issues
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetesrandomized controlled trial
